Bryan Faust, PhD

The biotech industry is built on one of the cleanest go-to-market strategies in existence: if you make a safe drug that really works, patients are likely to receive it and payors are likely to pay for it. Easy, right?

The complexity of biology notwithstanding, how can biotech teams convince prospective investors + partners they've thoughtfully minimized (or at least have mapped out) the risks inherent to drug discovery/development?

In this recent piece, @beckypferdehirt, @vintweeta and I synthesize our thoughts on a key node enabling the biotech financing (and in turn, medicine-creating) lifecycle -- the virtual data room.

a16z.com/virtual-data-r…

As AI masters the language of biology, the ways we interpret science, craft hypotheses, design cures, and fuel the broader bio-economy are poised for radical improvement. The recent explosion of models across the drug discovery lifecycle promises to usher in a new era of medicine.

Today, my @a16zbiohealth colleagues, @vijaypande, @beckypferdehirt, @zakdoric, and I published some of the most pressing “Jobs to be done” for AI in the life sciences.

Get the full insights here: a16z.com/ai-jobs-to-be-…

ATTN: fellow science nerds - Very excited for the reboot of our @a16zBioHealth Journal Club series! Vineeta Agarwala and I had a blast chatting with @yeo_lab and Ben Cravatt on their recent work underscoring the power of #chemoproteomics (1/2) bio-eats-world.simplecast.com/episodes/journ…

Interested in #autoimmune diseases, #GPCR's and signaling biology? How #autoantibodies can mimic hormone functions? Check out our preprint where we describe such molecular mimicry in the pathogenesis of Graves' disease. biorxiv.org/content/10.110… (1/9)